PT  - JOURNAL ARTICLE
AU  - Junko Kurita
AU  - Tamie Sugawara
AU  - Yoshiyuki Sugishita
AU  - Yasushi Ohkusa
TI  - Few Excess Mortality in Japan in August and October, 2020 since January, 2020
AID  - 10.1101/2020.07.09.20143164
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.09.20143164
4099  - http://medrxiv.org/content/early/2020/12/22/2020.07.09.20143164.short
4100  - http://medrxiv.org/content/early/2020/12/22/2020.07.09.20143164.full
AB  - Background As of the mid of December, 2020, the COVID-19 outbreak has been record the highest peak in November and December. Nevertheless, no remarkable excess mortality attributable to COVID-19 has been observed.Object We sought to quantify excess mortality in April using the National Institute of Infectious Diseases (NIID) model.Method We applied the NIID model to deaths of all causes from 1987 up through October, 2020 for the whole of Japan and up through July for Tokyo.Results Results show very few excess mortality in August and October, 2020 It was estimated as 12 and 104. Conversely, in Tokyo, no excess mortality was detected until July.Discussion and Conclusion This is the first time to detect excess mortality since the outbreak of COVID-19 had emerged in Japan. It might be important to continue to monitor excess mortality of COVID-19 carefully after October 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMinistry of Health, Labour and Welfare. Preliminary statistics on demographics https://www.mhlw.go.jp/toukei/list/81-1a.html